Supercomputers vs superbugs: GSK and Fleming Initiative target AMR
Biopharma company GSK and the Fleming Initiative are collaborating on six research programmes, called Grand Challenges, which seek to find new ways to slow the progress of antimicrobial resistance (AMR).